July 1, 2020

UPS NEXT DAY
SIGNATURE REQUIRED

John C. Rademacher, President and CEO
Option Care Enterprises, Inc.
3000 Lakeside Drive, Suite 300N
Bannockburn, IL 60015-5405

Dear Mr. Rademacher:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Option Care Enterprises, Inc, located at 1226 N Michael Drive Suite A, Wood Dale, Illinois 60191-1056, from September 1, 2016 to September 21, 2016, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Illinois State Board of Pharmacy for follow up.

When the Agency considers an inspection to be “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Russell Riley, Compliance Officer, at 630-323-2763 x. 101.
Sincerely,

Nicholas F. Lyons -S

Nicholas F. Lyons
Director, Compliance Branch
Division of Pharmaceutical Quality Operations III
Office of Regulatory Affairs
U.S. Food and Drug Administration

Enclosure: 1st party redacted EIR and SRL

CC: (cover letter only)
Dr. Yashwant Amin
Director of Drug Compliance
Division of Professional Regulation
100 W Randolph St
Suite 9-300
Chicago, IL 60601